Literature DB >> 34202601

Proposal of a Preoperative CT-Based Score to Predict the Risk of Clinically Relevant Pancreatic Fistula after Cephalic Pancreatoduodenectomy.

Marius Lucian Savin1,2, Florin Mihai1,2, Liliana Gheorghe1,2, Corina Lupascu Ursulescu1,2, Dragos Negru1,2, Ana Maria Trofin1,3, Mihai Zabara1,3, Vlad Nutu1,3, Ramona Cadar3, Mihaela Blaj1,4, Oana Lovin4, Felicia Crumpei3, Cristian Lupascu1,3.   

Abstract

Background and
Objectives: Postoperative pancreatic fistula after cephalic pancreatoduodenectomy (CPD) is still the leading cause of postoperative morbidity, entailing long hospital stay and costs or even death. The aim of this study was to propose the use of morphologic parameters based on a preoperative multisequence computer tomography (CT) scan in predicting the clinically relevant postoperative pancreatic fistula (CRPF) and a risk score based on a multiple regression analysis. Materials and
Methods: For 78 consecutive patients with CPD, we measured the following parameters on the preoperative CT scans: the density of the pancreas on the unenhanced, arterial, portal and delayed phases; the unenhanced density of the liver; the caliber of the main pancreatic duct (MPD); the preoperatively estimated pancreatic remnant volume (ERPV) and the total pancreatic volume. We assessed the correlation of the parameters with the clinically relevant pancreatic fistula using a univariate analysis and formulated a score using the strongest correlated parameters; the validity of the score was appreciated using logistic regression models and an ROC analysis.
Results: When comparing the CRPF group (28.2%) to the non-CRPF group, we found significant differences of the values of unenhanced pancreatic density (UPD) (44.09 ± 6.8 HU vs. 50.4 ± 6.31 HU, p = 0.008), delayed density of the pancreas (48.67 ± 18.05 HU vs. 61.28 ± 16.55, p = 0.045), unenhanced density of the liver (UDL) (44.09 ± 6.8 HU vs. 50.54 ± 6.31 HU, p = 0.008), MPD (0.93 ± 0.35 mm vs. 3.14 ± 2.95 mm, p = 0.02) and ERPV (46.37 ± 10.39 cm3 vs. 34.87 ± 12.35 cm3, p = 0.01). Based on the odds ratio from the multiple regression analysis and after calculating the optimum cut-off values of the variables, we proposed two scores that both used the MPD and the ERPV and differing in the third variable, either including the UPD or the UDL, producing values for the area under the receiver operating characteristic curve (AUC) of 0.846 (95% CI 0.694-0.941) and 0.774 (95% CI 0.599-0.850), respectively. Conclusions: A preoperative CT scan can be a useful tool in predicting the risk of clinically relevant pancreatic fistula.

Entities:  

Keywords:  clinically relevant pancreatic fistula; computer tomography; pancreatic volumetry; pancreatoduodenectomy

Mesh:

Year:  2021        PMID: 34202601     DOI: 10.3390/medicina57070650

Source DB:  PubMed          Journal:  Medicina (Kaunas)        ISSN: 1010-660X            Impact factor:   2.430


  29 in total

1.  Dual-phase computed tomography for assessment of pancreatic fibrosis and anastomotic failure risk following pancreatoduodenectomy.

Authors:  Yasushi Hashimoto; Guido M Sclabas; Naoki Takahashi; Yujiro Kirihara; Thomas C Smyrk; Marianne Huebner; Michael B Farnell
Journal:  J Gastrointest Surg       Date:  2011-09-27       Impact factor: 3.452

2.  Pancreatic anastomotic leak after the Whipple procedure is reduced using the surgical microscope.

Authors:  Keita Wada; L William Traverso
Journal:  Surgery       Date:  2006-06       Impact factor: 3.982

Review 3.  Clinical presentation of alcoholic liver disease and non-alcoholic fatty liver disease: spectrum and diagnosis.

Authors:  Praveen Sharma; Anil Arora
Journal:  Transl Gastroenterol Hepatol       Date:  2020-04-05

4.  A simple scoring system based on clinical factors related to pancreatic texture predicts postoperative pancreatic fistula preoperatively.

Authors:  Ulrich Friedrich Wellner; Gian Kayser; Hryhoriy Lapshyn; Olivia Sick; Frank Makowiec; Jens Höppner; Ulrich Theodor Hopt; Tobias Keck
Journal:  HPB (Oxford)       Date:  2010-12       Impact factor: 3.647

5.  Risk factors and outcomes in postpancreaticoduodenectomy pancreaticocutaneous fistula.

Authors:  John W Lin; John L Cameron; Charles J Yeo; Taylor S Riall; Keith D Lillemoe
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

6.  Fatty pancreas and increased body mass index are risk factors of pancreatic fistula after pancreaticoduodenectomy.

Authors:  Sébastien Gaujoux; Alexandre Cortes; Anne Couvelard; Séverine Noullet; Laurent Clavel; Vinciane Rebours; Philippe Lévy; Alain Sauvanet; Philippe Ruszniewski; Jacques Belghiti
Journal:  Surgery       Date:  2010-07       Impact factor: 3.982

7.  Estimated pancreatic parenchymal remnant volume accurately predicts clinically relevant pancreatic fistula after pancreatoduodenectomy.

Authors:  Mitsuro Kanda; Tsutomu Fujii; Masaya Suenaga; Hideki Takami; Masashi Hattori; Yoshikuni Inokawa; Suguru Yamada; Goro Nakayama; Hiroyuki Sugimoto; Masahiko Koike; Shuji Nomoto; Yasuhiro Kodera
Journal:  Surgery       Date:  2014-07-04       Impact factor: 3.982

8.  An analysis of risk factors for pancreatic fistula after pancreaticoduodenectomy: clinical impact of bile juice infection on day 1.

Authors:  Takahiro Kajiwara; Yoshihiro Sakamoto; Noriaki Morofuji; Satoshi Nara; Minoru Esaki; Kazuaki Shimada; Tomoo Kosuge
Journal:  Langenbecks Arch Surg       Date:  2009-08-05       Impact factor: 3.445

9.  Use of the time-signal intensity curve from dynamic magnetic resonance imaging to evaluate remnant pancreatic fibrosis after pancreaticojejunostomy in patients undergoing pancreaticoduodenectomy.

Authors:  Y Tajima; S Matsuzaki; J Furui; I Isomoto; K Hayashi; T Kanematsu
Journal:  Br J Surg       Date:  2004-05       Impact factor: 6.939

10.  A preoperative predictive score of pancreatic fistula following pancreatoduodenectomy.

Authors:  Keith J Roberts; James Hodson; Homoyoon Mehrzad; Ravi Marudanayagam; Robert P Sutcliffe; Paolo Muiesan; John Isaac; Simon R Bramhall; Darius F Mirza
Journal:  HPB (Oxford)       Date:  2013-11-08       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.